Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01009073 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
A Phase 1 study, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT01009073 is a Phase 1 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 51 participants.
The verdict
NCT01009073, a Phase 1 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
This is a three arm study to determine the maximum tolerated dose (MTD) of ABT-263 when administered in combination with erlotinib (Arm A), to determine the maximum tolerated dose (MTD) of ABT-263 when administered in combination with irinotecan (Arm B), and to evaluate safety of ABT-263 monotherapy (Arm C).
Interventions
- DRUG ABT-263
- DRUG erlotinib
- DRUG irinotecan (3-week schedule)
- DRUG irinotecan (weekly schedule)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2009-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01009073
The ClinicalTrials.gov registry entry for NCT01009073 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which ABT-263 is the first listed.
NCT01009073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01009073 about?
NCT01009073 is a clinical study titled "A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects". This is a three arm study to determine the maximum tolerated dose (MTD) of ABT-263 when administered in combination with erlotinib (Arm A), to determine the maximum tolerated dose (MTD) of ABT-263 when administered in combination with irinotecan (Arm B), and to evaluate safety of ABT-263 monotherapy...
What is the current status of trial NCT01009073?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2009-10. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01009073?
The interventions under investigation include: ABT-263 (DRUG), erlotinib (DRUG), irinotecan (3-week schedule) (DRUG), irinotecan (weekly schedule) (DRUG).
Who is sponsoring clinical trial NCT01009073?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.